Allogene Therapeutics Stock News

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced that it entered into a lease agreement to expand its headquarters in South San Francisco, California. The lease is expected to commence on April 1, 2022, and the additional 47,566 square feet of office and laboratory space will support the growth of its research platform and correlative clinical development activities.

One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 1.5 million shares of Allogene Therapeutics Inc.

The trading price of Allogene Therapeutics Inc. (NASDAQ:ALLO) closed lower on Monday, December 13, closing at $14.11, -21.74% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has earned a consensus recommendation of “Buy” from the seventeen research firms that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 1 year target price among brokers that […]

ARK Genomic ETF: Likely Economic Victim With Low Institutional Interest

SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced positive updated results from the Phase 1 UNIVERSAL study of single dose ALLO-715 in relapsed/refractory (r/r) multiple myeloma. Data were presented today in an oral session by Sham Mailankody, MBBS, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center in New York, during the 63 rd American Society of Hematology (ASH) Annual Meeting in Atlanta. This study utilizes ALLO-647, Allogene''s anti-CD52 monoclonal antibody, as a part of its differentiated lymphodepletion (LD) regimen.

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today reported updated data from two Phase 1 clinical trials (ALPHA and ALPHA2) of its lead anti-CD19 AlloCAR T therapy programs (ALLO-501 and ALLO-501A) at the 63 rd American Society of Hematology (ASH) Annual Meeting.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) shares gapped down prior to trading on Monday . The stock had previously closed at $19.09, but opened at $17.56. Allogene Therapeutics shares last traded at $17.49, with a volume of 652 shares changing hands. A number of analysts have recently issued reports on the company. Roth Capital reduced their target []

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) gapped down before the market opened on Monday . The stock had previously closed at $18.67, but opened at $18.25. Allogene Therapeutics shares last traded at $17.98, with a volume of 1,832 shares changing hands. ALLO has been the topic of several analyst reports. HC Wainwright restated a buy []

Allogene Therapeutics, Inc. (NASDAQ:ALLO) shares gapped down prior to trading on Monday . The stock had previously closed at $18.67, but opened at $18.25. Allogene Therapeutics shares last traded at $17.98, with a volume of 1,832 shares trading hands. A number of equities research analysts recently commented on the stock. William Blair reissued a buy []

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Equities research analysts expect Allogene Therapeutics, Inc. (NASDAQ:ALLO) to report earnings of ($0.60) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Allogene Therapeutics earnings, with estimates ranging from ($0.70) to ($0.53). Allogene Therapeutics posted earnings of ($0.53) per share during the same quarter last year, which []

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) have earned a consensus recommendation of Buy from the seventeen ratings firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12-month target price among brokerages that []